Daré Bioscience to Present at the 2019 BIO International Convention
May 29 2019 - 08:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that Sabrina Johnson, President and
Chief Executive Officer, will present at the 2019 BIO International
Convention on Tuesday, June 4, 2019, starting at 11:15 a.m. Eastern
Time in Philadelphia, PA.
The BIO International Convention brings together
the global biotechnology and pharmaceutical industry and is
expected to include over 500 education sessions and networking
opportunities with 16,000+ attendees from 67 countries.
The theme for the 2019 BIO International
Convention is “It Starts with One,” to highlight the critical daily
contributions that combine to bring new breakthroughs to the world,
and the women and men who bring new ideas and perspectives to the
forefront.
“Given our focus on identifying development and
global commercialization partners for our portfolio of women’s
health product candidates, we are pleased to have the opportunity
to present and participate in the partnering meetings organized by
the conference,” said Sabrina Johnson, President and CEO of Daré
Bioscience.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s sexual health, vaginal health,
fertility, and contraception. The company’s mission is to identify,
develop and bring to market a portfolio of novel, differentiated
therapies that expand treatment options, improve outcomes and
facilitate convenience for women in these targeted areas.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
non-hormonal, monthly contraceptive vaginal ring; Sildenafil Cream,
3.6%, a novel cream formulation of sildenafil to treat female
sexual arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver novel therapies
for women, please visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product candidates, clinical trials and
other matters. The information Daré posts on its investor relations
website or through social media channels may be deemed to be
material information. Daré encourages investors, the media, and
others interested in the company to review the information Daré
posts on its investor relations website
(https://darebioscience.gcs-web.com/) and to follow these Twitter
accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the
list of social media channels the company may use to communicate
information will be posted on the investor relations page of the
company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience,
Inc.:
Alex GrayBurns
McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:
Jordan PhillipsCanale
CommunicationsJordann@canalecomm.com619-849-6009
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2023 to Mar 2024